• HOME
  • NEWS
  • EXPLORE
    • CAREER
      • Companies
      • Jobs
    • EVENTS
    • iGEM
      • News
      • Team
    • PHOTOS
    • VIDEO
    • WIKI
  • BLOG
  • COMMUNITY
    • FACEBOOK
    • INSTAGRAM
    • TWITTER
Tuesday, November 17, 2026
BIOENGINEER.ORG
No Result
View All Result
  • Login
  • HOME
  • NEWS
  • EXPLORE
    • CAREER
      • Companies
      • Jobs
        • Lecturer
        • PhD Studentship
        • Postdoc
        • Research Assistant
    • EVENTS
    • iGEM
      • News
      • Team
    • PHOTOS
    • VIDEO
    • WIKI
  • BLOG
  • COMMUNITY
    • FACEBOOK
    • INSTAGRAM
    • TWITTER
  • HOME
  • NEWS
  • EXPLORE
    • CAREER
      • Companies
      • Jobs
        • Lecturer
        • PhD Studentship
        • Postdoc
        • Research Assistant
    • EVENTS
    • iGEM
      • News
      • Team
    • PHOTOS
    • VIDEO
    • WIKI
  • BLOG
  • COMMUNITY
    • FACEBOOK
    • INSTAGRAM
    • TWITTER
No Result
View All Result
Bioengineer.org
No Result
View All Result
Home NEWS Science News Health

Information-Based Prescription Review Systems Evolve from Manual Screening to Intelligent Interception

by
November 16, 2026
in Health
Reading Time: 6 mins read
0
Information-Based Prescription Review Systems Evolve from Manual Screening to Intelligent Interception

Information-Based Prescription Review Systems Evolve from Manual Screening to Intelligent Interception

Share on FacebookShare on TwitterShare on LinkedinShare on RedditShare on Telegram

A recent narrative review published in Frontiers in Digital Health examines the evolution, technical architecture, and clinical utility of information-based drug prescription review systems. As healthcare environments become increasingly complex, manual review processes—traditionally performed by pharmacists relying on individual expertise and visual inspection—have struggled to keep pace with the volume of drug information and clinical workloads. The study characterizes the development of these systems as a journey through three distinct, cumulative stages: the integration of basic electronic format verification in the late 20th century, the adoption of rule-based engines in the early 21st century, and the recent incorporation of big data, machine learning, and artificial intelligence (AI). While these advancements have enabled real-time, standardized interception of prescription risks at scale, the review underscores that technology is not a panacea, and the effectiveness of such systems in reducing patient-level outcomes like mortality or readmissions remains inconsistently documented in the current evidence base.

The development history of information-based review reflects an increasing shift toward dynamic, intelligent assessment. The initial stage from the 1970s to the 1990s focused on rudimentary electronic transmission and format checks. The second stage, spanning the 1990s to the early 21st century, saw the mainstreaming of rule engines based on clinical guidelines and drug knowledge bases, which, while automating review, were often rigid and prone to high false-positive rates. Since 2010, the integration of AI, machine learning, and natural language processing has allowed systems to parse unstructured clinical text and mine historical data for personalized risk assessment. Despite the excitement surrounding AI, the review emphasizes that rule-based engines continue to serve as the core backbone of most deployed systems, providing a deterministic and auditable foundation that newer, probabilistic models struggle to replicate in terms of clear interpretability and validation.

A complete drug prescription review information system is typically defined by a five-layer technical architecture designed to support continuous closed-loop evolution. At the bottom lies the data integration layer, which acts as the system’s data hub by aggregating multi-source information from hospital information systems, electronic medical records, and pharmacy management systems using application programming interfaces and stream computing frameworks. Above this, the knowledge base and rule engine form the system’s “cognitive core,” utilizing ontology modeling and knowledge graphs to transform static medical data into computable logic. The audit and decision engine serves as the central processing unit, executing sequenced review pipelines that range from simple allergy checks to complex dosage calculations. Finally, the system includes a human-machine interaction interface for clinicians and a feedback mechanism that allows pharmacists to refine the system’s knowledge and rule thresholds, theoretically creating a loop of continuous improvement.

These systems are implemented through several distinct application models, each serving different clinical and management purposes. Pre-review models operate synchronously, embedding the review node directly into the physician’s ordering workflow to intercept high-risk issues like explicit contraindications before a prescription is finalized. Post-review models, by contrast, function asynchronously in batch processing modes to provide in-depth retrospective analysis, supporting medication quality management and long-term strategy optimization. Special review models offer customized, deep audits for high-risk scenarios such as perioperative antibiotic use or cancer therapy, often requiring complex time-series data analysis. Regional collaborative models represent a newer frontier, aggregating prescription data from multiple institutions onto a centralized cloud platform, thereby potentially extending high-level expert review capabilities to resource-limited primary care settings.

The benefits associated with these systems are multifaceted but often reside in the realm of process improvement rather than clinical endpoint reduction. By automating repetitive verification, information-based systems have demonstrably reduced the rate at which recognizable prescribing errors reach patients, with meta-analyses of computerized order entry showing roughly half as many preventable adverse drug events compared to manual processes. Productivity is also enhanced as institutions move from a labour-intensive, post-factum review model to an automated, preemptive alert system. Furthermore, these tools support the broader transformation of pharmaceutical care, allowing pharmacists to shift their attention from verifying order correctness to higher-value activities such as bedside medication reconciliation, therapeutic drug monitoring, and antimicrobial stewardship, which are areas where pharmacist-led interventions have shown the most consistent and substantial impact on patient care.

Despite these operational gains, the study highlights critical challenges regarding system limitations and data quality. The accuracy of any automated review is strictly bounded by the completeness and accuracy of the underlying electronic patient data. Missing diagnoses, outdated allergy history, or incorrectly entered test results can lead the system to generate misleading alerts or fail to detect genuine risks. Furthermore, systems frequently struggle with “clinical wisdom,” finding it difficult to account for the nuanced trade-offs necessary in treating complex, multimorbid patients. Some studies have even identified system-attributable errors, where interface behavior, default values, or workflow gaps inadvertently create new risks for the patient, suggesting that the net error rate and severity distribution must be carefully monitored rather than assumed to be positive.

Clinical adaptability and alert fatigue remain the most persistent barriers to successful implementation. When systems present too many low-value warnings, clinicians develop alert fatigue, leading to override rates that in some studies range from 49% to 96%. This phenomenon is not merely a software annoyance but a failure of the safety net, as constant interruptions may cause busy clinicians to dismiss even high-consequence warnings. Automation bias also complicates the picture, as users may implicitly trust system advice even when clinical context suggests otherwise, potentially eroding the critical thinking skills of both pharmacists and physicians. The review suggests that alert configuration should be managed as a clinical governance issue rather than a technical setting, with specific ownership and clear processes for monitoring override behavior as a quality indicator.

Legal, ethical, and governance challenges pose further obstacles, particularly regarding the ambiguity of responsibility in the event of an automated system failure. When a system misses or incorrectly intercepts a prescription, it remains unclear how liability is apportioned between the physician, the pharmacist, the software developer, and the healthcare institution. This lack of clear legal definitions for AI-assisted decision-making may prompt clinicians to either ignore the system entirely or over-rely on it to avoid personal accountability. Additionally, the “black box” nature of some advanced machine learning models limits explainability, which hinders the patient’s right to informed consent and the clinician’s ability to contest or verify an automated recommendation, thus challenging the principles of transparency and professional autonomy.

Implementation of these systems also involves significant explicit and implicit costs that are rarely fully accounted for in existing economic literature. While gross savings in drug expenditures are often cited, these figures frequently overlook the substantial investments required for software procurement, system integration, continuous rule maintenance, and the training of personnel. Furthermore, the recurrent nature of rule-base maintenance creates ongoing financial pressure, which can be particularly daunting for resource-limited institutions. The study warns that without a rigorous economic analysis that nets out these costs and incorporates the lack of consistent evidence for reductions in mortality or hospital admissions, the assumed cost-effectiveness of these systems should be viewed with caution.

Context dependence remains a defining limitation, as review systems are not portable commodities but highly localized tools. Performance is deeply tied to the specific formulary, coding systems, clinical guidelines, and prescribing culture of the setting where the software is deployed. Most research has been conducted in high-income, academic, single-centre environments, leaving significant gaps in the evidence for the generalizability of these tools in different geographical or clinical contexts. Equity concerns are also paramount, as algorithms trained on historical data may inadvertently encode and reproduce existing treatment disparities. The review emphasizes that any successful deployment requires careful validation within the specific setting of use, rather than a one-size-fits-all adoption of performance figures reported in the academic literature.

Looking to the future, the development of information-based drug prescription review is trending toward deeper integration, standardization, and a human-centered design philosophy. Projections indicate a shift toward full-process closed-loop management, where review functions are integrated seamlessly from the moment a drug is prescribed until the patient’s final efficacy follow-up. While technologically plausible, the realization of such a vision depends on advancements in regional interoperability and the establishment of unified data standards like HL7 FHIR. The study concludes that the future value of these systems will depend less on increasing algorithmic sophistication and more on successful validation in real-world settings, the governance of shared knowledge bases, and the explicit definition of professional accountability for decisions made in collaboration with automated agents.

Subject of Research: Information-based drug prescription review and clinical informatics

Article Title: From manual screening to intelligent interception: the information-based evolution and future outlook of drug prescription review

Article References: Le, J., Wu, T., & Qin, S. (2026). From manual screening to intelligent interception: the information-based evolution and future outlook of drug prescription review. Frontiers in Digital Health, 8, 1987514. https://doi.org/10.3389/fdgth.2026.1987514

Image Credits: AI Generated

DOI: 10.3389/fdgth.2026.1987514

Keywords: medication safety, clinical decision support, health informatics, artificial intelligence, alert fatigue, pharmacotherapy, electronic prescribing, prescription review, data standardization, hospital information systems, healthcare technology, clinical pharmacy, medication errors, rational drug use, interoperability, digital health, pharmaceutical care, algorithmic governance

News Source: Blake Davidson. (November 16, 2026). Information-Based Prescription Review Systems Evolve from Manual Screening to Intelligent Interception. Scienmag.

Tags: alert fatiguealgorithmic governanceArtificial IntelligenceClinical decision supportclinical pharmacydata standardizationDigital Healthelectronic prescribinghealth informaticsHealthcare Technologyhospital information systemsinteroperabilitymedication errorsMedication safetypharmaceutical carePharmacotherapyprescription reviewrational drug use
Share12Tweet7Share2ShareShareShare1

Related Posts

Study Identifies Four Motivations for Women Terminating Unwanted Pregnancies

Study Identifies Four Motivations for Women Terminating Unwanted Pregnancies

November 17, 2026
3D Facial Scan Integration of Dental Models Shows Low Clinical Error

3D Facial Scan Integration of Dental Models Shows Low Clinical Error

November 17, 2026

Exome and Copy Number Analysis Diagnose 31.7 Percent of Pediatric Immune Cases

November 17, 2026

Prostate Cancer PSA Trajectories Before Surgery Predict Postoperative Event-Free Survival Outcomes

November 17, 2026

POPULAR NEWS

  • De Novo Unbalanced X;14 Translocation Linked to Turner Syndrome Phenotype

    De Novo Unbalanced X;14 Translocation Linked to Turner Syndrome Phenotype

    29 shares
    Share 12 Tweet 7
  • Nepal Survey Finds Stable Drug-Resistant Tuberculosis Rates Alongside Rising Fluoroquinolone Resistance

    29 shares
    Share 12 Tweet 7
  • Systematic Review Finds No Clear Mortality Benefit Across Six Sepsis Treatments

    29 shares
    Share 12 Tweet 7
  • Surgical Internet of Medical Things Faces Cyber Threats Endangering Patient Safety

    29 shares
    Share 12 Tweet 7

About

We bring you the latest biotechnology news from best research centers and universities around the world. Check our website.

Follow us

Recent News

Study Identifies Four Motivations for Women Terminating Unwanted Pregnancies

3D Facial Scan Integration of Dental Models Shows Low Clinical Error

Exome and Copy Number Analysis Diagnose 31.7 Percent of Pediatric Immune Cases

Subscribe to Blog via Email

Enter your email address to subscribe to this blog and receive notifications of new posts by email.

Join 88 other subscribers
  • Contact Us

Bioengineer.org © Copyright 2023 All Rights Reserved.

Welcome Back!

Login to your account below

Forgotten Password?

Retrieve your password

Please enter your username or email address to reset your password.

Log In
No Result
View All Result
  • Homepages
    • Home Page 1
    • Home Page 2
  • News
  • National
  • Business
  • Health
  • Lifestyle
  • Science

Bioengineer.org © Copyright 2023 All Rights Reserved.